Inner Ear Diseases: Novel Drug Delivery Approaches

News provided by

Nov 26, 2014, 07:30 ET

DUBLIN, Nov. 26, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Inner Ear Diseases: Novel Drug Delivery Approaches" report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769

A significant proportion of the world's population is suffering from otologic diseases. Absence of any disease modifying drugs is a big unmet need in the market. The current treatment of inner ear diseases is primarily based on counselling, electric and magnetic nerve stimulations.

At the same time, there is a growing off-label use of drugs for symptomatic relief. Cochlear implants, brainstem implants and hearing aids are other commonly available options to the patients to overcome hearing damages. However, these options do suffer from several limitations such as high cost, poor sound quality, and painful surgeries (in case of implants).

The widening gap between the demand and supply of drugs is likely to provide a major impetus to the market in the coming decade. The drugs for direct delivery to inner ear are currently under development and, once approved, are likely to gain a major share of the market.

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INNER EAR: AN INTRODUCTION

4. INNER EAR DRUG DELIVERY: PIPELINE ANALYSIS

5. DIRECT DRUG DELIVERY TO INNER EAR: INTRATYMPANIC, INTRACOCHLEAR, TRANSTYMPANIC AND INTRALABYRINTHINE ROUTES OF DELIVERY

6. CASE STUDIES

7. COCHLEAR IMPLANTS (BIONIC EARS)

8. INTERVIEW TRANSCRIPTS

9. CONCLUSION

10. APPENDIX 1: TABULATED DATA

11. APPENDIX 2: LIST OF COMPANIES

Companies Mentioned: